x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Kishnani, Priya SRemove Kishnani, Priya S filter
- Case, Laura ERemove Case, Laura E filter
Author
- Watson, Michael S2
- Arn, Pamela1
- Austin, Stephanie L1
- Bali, Deeksha1
- Bali, Deeksha S1
- Berger, Kenneth1
- Boney, Anne1
- Byrne, Barry J1
- Chung, Wendy K1
- Crowley, John F1
- Desai, Dev M1
- Downs, Steven1
- El-Gharbawy, Areeg1
- Haller, Ronald1
- Hobson-Webb, Lisa D1
- Howell, R Rodney1
- Kravitz, Richard M1
- Mackey, Joanne1
- Marsden, Deborah1
- Martins, Anna Maria1
- Millington, David S1
- Nicolino, Marc1
- O'grady, Gwen1
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
2 Results
- ACMG-Practice-GuidelinesOpen Archive
Glycogen Storage Disease Type III diagnosis and management guidelines
Genetics in MedicineVol. 12Issue 7p446–463Published in issue: July, 2010- Priya S. Kishnani
- Stephanie L. Austin
- Pamela Arn
- Deeksha S. Bali
- Anne Boney
- Laura E. Case
- and others
Cited in Scopus: 191Glycogen storage disease type III is a rare disease of variable clinical severity affecting primarily the liver, heart, and skeletal muscle. It is caused by deficient activity of glycogen debranching enzyme, which is a key enzyme in glycogen degradation. Glycogen storage disease type III manifests a wide clinical spectrum. Individuals with glycogen storage disease type III present with hepatomegaly, hypoglycemia, hyperlipidemia, and growth retardation. Those with type IIIa have symptoms related to liver disease and progressive muscle (cardiac and skeletal) involvement that varies in age of onset, rate of disease progression, and severity. - ACMG Practice GuidelinesOpen Archive
Pompe disease diagnosis and management guideline
Genetics in MedicineVol. 8Issue 5p267–288Published in issue: May, 2006- Priya S. Kishnani
- Robert D. Steiner
- Deeksha Bali
- Kenneth Berger
- Barry J. Byrne
- Laura E. Case
- and others
Cited in Scopus: 432Disclaimer: ACMG standards and guidelines are designed primarily as an educational resource for physicians and other health care providers to help them provide quality medical genetic services. Adherence to these standards and guidelines does not necessarily ensure a successful medical outcome. These standards and guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the geneticist should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.